{"id":"uft-adjuvant-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Hand-foot syndrome"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"UFT combines uracil with tegafur, a prodrug that is metabolized to fluorouracil (5-FU), a classic antimetabolite chemotherapy agent. The fluorouracil component inhibits thymidylate synthase, blocking dTMP synthesis and disrupting DNA replication in rapidly dividing cancer cells. Uracil acts as a modulator to enhance and prolong the cytotoxic effects of fluorouracil.","oneSentence":"UFT is a combination of uracil and tegafur (a prodrug of fluorouracil) that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:15.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant chemotherapy for colorectal cancer"},{"name":"Gastric cancer adjuvant treatment"}]},"trialDetails":[{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT02363400","phase":"PHASE3","title":"A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2014-12-14","conditions":"Nasopharyngeal Carcinoma","enrollment":10},{"nctId":"NCT03811652","phase":"PHASE1","title":"A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2018-12-20","conditions":"Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC)","enrollment":8},{"nctId":"NCT00392899","phase":"PHASE3","title":"Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2006-10","conditions":"Colorectal Cancer","enrollment":2025},{"nctId":"NCT00898846","phase":"","title":"Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2006-10","conditions":"Colorectal Cancer","enrollment":1111},{"nctId":"NCT00190515","phase":"PHASE3","title":"A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)","status":"COMPLETED","sponsor":"Haruhiko Fukuda","startDate":"2003-02","conditions":"Colorectal Neoplasms","enrollment":1101},{"nctId":"NCT00147147","phase":"PHASE3","title":"Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2)","status":"COMPLETED","sponsor":"Japan Clinical Oncology Group","startDate":"1993-01","conditions":"Gastric Neoplasm","enrollment":280},{"nctId":"NCT00336947","phase":"PHASE3","title":"S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer","status":"UNKNOWN","sponsor":"Yokohama City University","startDate":"2006-04","conditions":"Head and Neck Cancer","enrollment":500},{"nctId":"NCT00855881","phase":"PHASE2","title":"Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Mackay Memorial Hospital","startDate":"2008-12","conditions":"Head and Neck Cancer","enrollment":115},{"nctId":"NCT00152230","phase":"PHASE3","title":"A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"1996-10","conditions":"Colorectal Cancer","enrollment":900},{"nctId":"NCT00152243","phase":"PHASE3","title":"A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"1997-06","conditions":"Gastric Cancer","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":415,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adjuvant chemotherapy with tegafur-uracil"],"phase":"phase_3","status":"active","brandName":"UFT adjuvant chemotherapy","genericName":"UFT adjuvant chemotherapy","companyName":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","companyId":"translational-research-center-for-medical-innovation-kobe-hyogo-japan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"UFT is a combination of uracil and tegafur (a prodrug of fluorouracil) that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells. Used for Adjuvant chemotherapy for colorectal cancer, Gastric cancer adjuvant treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}